6 Results for "

MCL REC-1

" in MedChemExpress (MCE) Product Catalog:
Products (6)

6 Results for "MCL REC-1" in MCE Product Catalog:

10
10 Cited Publications
Cat. No.: HY-137471
CAS No.: 2682114-39-0
Purity:  99.80%
Synonyms: RIN1
Target:  

Notch

Research Areas:  

Cancer

RBPJ Inhibitor-1 (RIN1), the first RBPJ inhibitor, blocks the functional interaction of RBPJ with SHARP. RBPJ Inhibitor-1 (RIN1) inhibits NOTCH-dependent tumor cell proliferation .
loading...
    loading...
Cat. No.: HY-136250
CAS No.: 2349356-09-6
Purity:  99.76%
Target:  

PROTACs CDK

Research Areas:  

Cancer

BSJ-03-204 is a PROTAC linking a Cereblon ligand to a CDK ligand, serving as a potent and selective dual degrader of CDK4/6. BSJ-03-204 exhibits IC50 values of 26.9 nM and 10.4 nM against CDK4/D1 and CDK6/D1, respectively. BSJ-03-204 can be utilized for cancer-related research .
loading...
    loading...
Cat. No.: HY-148683
CAS No.: 2377113-41-0
Purity:  98.77%
Target:  

Arp2/3 Complex

Research Areas:  

Cancer

EG-011 is the first-in-class and potent Wiskott-Aldrich syndrome protein (WASP) activator. EG-011 activates the auto-inhibited form of WASP with strong actin polymerization. EG-011 has selective anti-tumor activity in lymphomas .
loading...
    loading...
Cat. No.: HY-137438
CAS No.: 1858206-58-2
Purity:  99.75%
Synonyms: TG-1701
Target:  

Btk

Research Areas:  

Cancer

Edralbrutinib (TG-1701) is a highly selective, orally available irreversible BTK inhibitor, with an EC50 of 6.70 nM and a Kd of 3 nM against human BTK. Edralbrutinib inhibits downstream signaling of the B cell receptor, induces dephosphorylation of Ikaros Ser442/445, promotes nuclear exclusion of Ikaros, attenuates Ikaros gene signatures, and exerts anti-tumor activity. Edralbrutinib can be used in research related to B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma, follicular lymphoma, and diffuse large B-cell lymphoma .
loading...
    loading...
Cat. No.: HY-136250A
Purity:  99.87%
Target:  

PROTACs CDK

Research Areas:  

Cancer

BSJ-03-204 triTFA is a PROTAC connected by ligands for Cereblon and CDK. BSJ-03-204 triTFA is a potent and selective Palbociclib-based CDK4/6 dual degrader (PROTAC), with IC50s of 26.9 nM and 10.4 nM for CDK4/D1 and CDK6/D1, respectively. BSJ-03-204 triTFA does not induce IKZF1/3 degradation and has anti-cancer activity .
loading...
    loading...
Cat. No.: HY-181623
CAS No.: 3114684-06-6
Target:  

PROTACs Btk

Research Areas:  

Cancer

PROTAC BTK degrader-14 (compound 112) is a PROTAC protein degrader targeting BTK. PROTAC BTK degrader-14 can be used for the research of cancer .
loading...
    loading...